Results 71 to 80 of about 874,981 (155)

CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions. [PDF]

Mol Med
Cohen-Solal JF, Pohl CS, Cummings SM, Gygi JP, Safikhani Z, Bartocha B, Buckley CD, Dong Y, Eyerich K, Karsen SD, Lynch GR, Macoritto M, Morisset PA, Nelson OD, Radstake T, Rieder F, Rivas J, Savaryn JP, Smith KM, Stulir M, Szynal C, Tylek C, Veldman GM, Wasserman LG, Westmoreland S, Chaudhary N, Staron MM.   +26 more
europepmc   +1 more source

Is anti‐IL‐17 faster and anti‐IL‐23 better for psoriasis patients after adalimumab failure?

JEADV Clinical Practice
Xiaojun Shi, Keke Li, Chen Li
doaj   +1 more source

Bullous pemphigoid induced by anti-IL-23 monoclonal antibody in a psoriatic patient: a case report. [PDF]

Front Med (Lausanne)
Xi R, Cao Y, Zhuang Q, Ma L, Tao M, Li Y.   +5 more
europepmc   +1 more source

Systemic Immune-Inflammation Index (SII) as a Predictive Biomarker of Therapeutic Response in Psoriasis: A Retrospective Comparative Analysis of Anti-TNF, Anti-IL-17, and Anti-IL-23 Agents. [PDF]

J Pers Med
Trovato E, La Marca F, Simonini B, Dragotto M, Calandra E, Lussana F, Cartocci A, Rubegni P.   +7 more
europepmc   +1 more source

Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study. [PDF]

J Clin Med
Di Giulio S, Falcidia C, Foggi G, Bianco M, Gargiulo L, Valenti M, Costanzo A, Narcisi A, Ibba L.   +8 more
europepmc   +1 more source

Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis. [PDF]

Life (Basel)
Annunziata G, Scala E, Mercurio L, Sanna L, Dattolo A, Pagnanelli G, Lolli MG, Belli R, Moretta G, Savastano S, Muscogiuri G, Maisto M, Ciampaglia R, Piccolo V, Tenore GC, Albanesi C, Madonna S, Barrea L.   +17 more
europepmc   +1 more source

Clinical Trial to Assess the Safety and Tolerability of Anti-IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol-Associated Liver Disease. [PDF]

Aliment Pharmacol Ther
Diaz LA, Morris S, Dave S, Kim SM, Sarik W, Richards L, Madamba E, Bettencourt R, Fulinara C, Pham T, Miller G, Carvalho-Gontijo Weber R, Momper JD, He F, Jain S, Jamieson C, Kisseleva T, Brenner D, Loomba R.   +18 more
europepmc   +1 more source

Structural Basis for p19 Targeting by Anti-IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. [PDF]

JID Innov
Daniele SG, Eldirany SA, Damiani G, Ho M, Bunick CG.   +4 more
europepmc   +1 more source

Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis. [PDF]

Dermatol Ther (Heidelb)
Hsieh CY, Hsu FL, Tsai TF.
europepmc   +1 more source

IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4⁺ T-cell responses. [PDF]

J Immunother Cancer
Guo Y, Wang M, Xuan Y, Pan L, Yan W, Cheng J, Yu Y, Wang X, Xu L, Sun X, Han R, Si L, Wang Y, Li S, Wang P.   +14 more
europepmc   +1 more source